Trial Profile
A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms TOURMALINE-MM5
- Sponsors Takeda Oncology
- 04 Apr 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database record (26 Nov 2021).
- 25 Oct 2021 Planned End Date changed from 16 Jun 2021 to 30 Nov 2021.
- 15 Jun 2021 Planned primary completion date changed from 17 Sep 2020 to 16 Jun 2021.